Drugs / CD7.CAR/28zeta CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03690011 | Aug 2021 → Mar 2026 overdue | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Baylor College of Medicine | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD7.CAR/28zeta CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03690011 ↗ |
| Modality | Cell therapy | “Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person.” NCT03690011 ↗ |
| Route | Intravenous | “Patients will be given an injection of cells into the vein through an IV at the assigned dose.” NCT03690011 ↗ |